CA
NZ
UK
AU
IND
US
KALA BIO, Inc. (NASDAQ: KALA) submitted a prospectus supplement for an at-the-market equity offering to potentially sell as much as $250 million in common stock, and shares closed down 17% at $0.61 on the news. The filing gives the company flexibility to sell shares …
X4 Pharmaceuticals (NASDAQ:XFOR) is a biopharmaceutical company focused on rare diseases. Its lead product, mavorixafor, is an oral therapy developed for certain rare immunologic conditions, and the company has pursued additional indications for the drug.
Femasys (NASDAQ:FEMY) is a biomedical company developing reproductive-health devices. Its portfolio includes FemaSeed for intratubal insemination, FemBloc for non-surgical permanent birth control, FemVue for fallopian-tube ultrasound diagnostics, and related fertility and diagnostic tools.
Inhibikase Therapeutics (NASDAQ:IKT) is a clinical-stage pharmaceutical company focused on cardiopulmonary disease. Its lead candidate, IKT-001, a prodrug formulation of imatinib, is being developed for pulmonary arterial hypertension (PAH), an orphan condition affecting roughly 50,000 Americans.
Neuphoria Therapeutics (NASDAQ:NEUP) is a clinical-stage biotechnology company that has focused on neuropsychiatric disorders. Its prior lead candidate, BNC210, was being developed for post-traumatic stress disorder, but that program was halted after a Phase 3 trial failure in October 2025.
NovoCure (NASDAQ:NVCR) is an oncology company that develops and commercializes Tumor Treating Fields (TTFields) therapy, delivered through its Optune platform. TTFields use electric fields to disrupt cancer-cell division, and the therapy is applied via wearable devices.
PolyPid (NASDAQ:PYPD) is a clinical-stage biopharmaceutical company developing locally administered, prolonged-release therapies. Its lead program targets the prevention of surgical-site infections, delivering an antibiotic directly at the surgical site over an extended period.
SciSparc (NASDAQ:SPRC) is a clinical-stage pharmaceutical company developing cannabinoid-based therapeutics. Its pipeline includes SCI-110 for Tourette syndrome and Alzheimer's-related agitation, SCI-210 for autism spectrum disorder and seizures, and CannAmide for chronic pain. The company also markets hemp seed oil products.
Thermo Fisher Scientific (NYSE:TMO) is a global provider of scientific instrumentation, reagents and consumables, software and services supporting research, clinical and industrial laboratories. Its business spans life-sciences solutions, analytical instruments, specialty diagnostics and laboratory products, including contract manufacturing for pharmaceutical and biotech customers.
Polyrizon (NASDAQ:PLRZ) is a development-stage biotech specializing in intranasal hydrogel products. Its core 'Capture and Contain' technology forms a thin protective barrier in the nasal cavity, and its pipeline includes NASARIX (an allergy blocker), a viral blocker for respiratory viruses, and an intranasal naloxone …
Please wait processing your request...